Intermolecularが2018年第1四半期の決算を発表 （前半）

AsiaNet 73449 （0820）

【サンノゼ（米カリフォルニア州）2018年5月9日PR Newswire＝共同通信JBN】

＊3期連続でポジティブな調整済みEBITDA（利払い前・税引き前・減価償却前利益）を達成

先端材料イノベーションの信頼されるパートナーであるIntermolecular, Inc.（NASDAQ: IMI）は9日、2018年3月31日に終了した第1四半期の決算を発表した。

▽2018年第1四半期の財務・運営業績ハイライト

＊総売上高は970万ドルと前期比8％減、前年同期比3％減。

＊プログラム売上高は四半期連続で5％増、前年同期比36％増。

＊第1四半期の調整済みEBITDAは100万ドル（売上高の10％）、前年同期の調整済みEBITDAは190万ドルの損失。

＊総現金・投資は140万ドル増の2720万ドル。

＊同四半期中に新たに2件の契約を確保。

▽経営陣のコメント

Intermolecularのクリス・クレイマー社長兼最高経営責任者（CEO）は「2018年第1四半期はIntermolecularにとって3期連続でポジティブな調整済みEBITDAを記録した。これは2013年以来初の一貫性を示すものだ。当社の財務実績の改善は過去1年にわたり、われわれが顧客エンゲージメントを拡大し、コスト構造を削減するために取った行動の結果である。具体的には、われわれは前年同期比ベースで第1四半期にプログラムサービスの売上高を240万ドル、すなわち36％増加させるとともに、営業経費を450万ドル削減した。この組み合わせはレガシー・プログラムからのロイヤルティーの予定された期限満了を相殺しただけでなく、持続可能な収益性の鍵となっている。当社の既存の顧客と新規の顧客との契約は引き続き拡大しており、われわれは当社の事業収益性を継続して成長、拡大していく能力に自信を持っている」と述べた。

▽2018会計年度第1四半期の実績

2018年第1四半期の売上高は970万ドルで、2017年第4四半期の1050万ドルに比べ8％減、前年同期の990万ドルに比べ3％減となった。プログラム売上高は930万ドルで前期比5％増、前年同期比36％増だった。

2018年第1四半期の純損失は60万ドル、1株当たり0.01ドルの損失だった。2017年第4四半期は10万ドルの純利益、1株当たり0.00ドルの利益で、前年同期は純損失580万ドル、1株当たり0.12ドルの損失だった。

2018年第1四半期のNon-GAAP純損失は40万ドル、1株当たり0.01ドルの損失だった。前四半期は40万ドルのnon-GAAP純利益、1株当たり0.01ドルの利益で、前年同期は520万ドルのnon-GAAP純損失、1株当たり0.10ドルの損失だった。

2018年第1四半期の調整済みEBITDAは100万ドルだった。前四半期の調整済みEBITDAは210万ドル、前年同期の調整済みEBITDA損失は190万ドルだった。

2018年第1四半期末の現金・投資は2720万ドルと、2017年第4四半期末の2580万ドルから140万ドル増加した。

▽2018年第2四半期見通し

以下の記述は、2018年6月30日に終了する第2四半期に関するIntermolecularの現在の見通しに基づいている。以下の見通しは将来の見通しに関するものであり、実際の業績は、市場条件および下記の「将来の見通しに関する記述」に記載されている要因によって大きく異なる可能性がある。Intermolecularは今後、この見通しの更新を予定しておらず、将来この見通しを更新するいかなる義務も負わない。

＊売上高は980万－1020万ドルと見込まれる。

＊純利益は30万ドルの損失（1株当たり0.01ドルの損失）から30万ドルの利益（1株当たり0・01ドルの利益）の間と予測される。発行済み株式数が約4960万株との前提に基づく。

＊株式報酬費用を除くNon-GAAP純利益は、損益ゼロ－60万ドルの利益、1株当たり0.00－0.01ドルと予測される。発行済み株式数が4960万株との前提に基づく。

＊調整済みEBITDAは120万－170万ドルと予測される。

Intermolecularは米国一般会計基準（GAAP）に従い、そして追加的に非GAAPベースで、売上高、売上原価、粗利益、営業利益（損失）、純利益（純損失）および1株当たり利益（損失）を報告している。非GAAP財務指標と最も直接的に比較可能なGAAP指標との調整、並びに非GAAP指標から除外された項目の記述は、本プレスリリースの財務諸表に含まれている。以下の「GAAPと非GAAP財務指標との調整」および「GAAP純利益／損失から非GAAP純利益への調整」を参照。

▽カンファレンスコール

Intermolecularは米東部時間2018年5月8日午後5時（米太平洋時間午後2時）からカンファレンスコールおよび同時ウェブキャスト（音声のみ）を開催し、これらの業績について議論する。カンファレンスコールはIntermolecularのクリス・クレイマー社長兼CEOおよびビル・ロシュレイン最高財務責任者（CFO）が主催する。

直通電話番号

米国：+1 (877) 251-1860

海外から：+1 (224) 357-2386

Conference ID：2183689

開始時間の5－10分前に上記の番号に電話を。オペレーターがあなたの名前と組織を登録する。カンファレンスコールとの接続が困難な場合には、+1 (949) 574-2386に電話し、Liolios Groupと接触を。

カンファレンスコールの生放送およびウェブキャスト（音声のみ）は、終了後最長30日間、Intermolecularのウェブサイト（http://ir.intermolecular.com/ ）で利用可能。

▽Intermolecular, Inc.について

Intermolecular（R）は先端素材イノベーションの信頼されるパートナーである。先端素材は、半導体、家電、自動車、航空宇宙を含む幅広い産業のための21世紀におけるイノベーションの中核である。Intermolecularは豊富な素材に関する専門知識、加速学習・実験プラットフォーム、そして情報・分析インフラストラクチャーで、10年間にわたり大手企業が素材イノベーションを加速し、リスクを極小化するのをサポートしてきた。

詳細は、www.intermolecular.com.を参照。

「Intermolecular」およびIntermolecularロゴは登録商標である。不許複製。

▽非GAAP財務指標

当社はまた、GAAPベースで提示された財務データを補足するため、株式報酬費用の影響を除いた特定の非GAAP財務指標を開示している。これらの非GAAP財務指標は、GAAPに準拠して作成されたものではなく、GAAPに代わるものでもない。他の企業が開示した非GAAP財務情報とは異なる方法で算出される可能性もある。これらの結果は、当社の業績をそれと対応するGAAP指標と併せて評価するためにのみ使用される必要がある。われわれは、非GAAP財務指標は経営陣がIntermolecularの中核事業の業績の外にあると判断した費用を除外しているため、非GAAP財務情報は経営陣および投資家に対し、当社の財務状態および経営成績に関連する財務および事業の傾向に関する有益な情報を提供すると考えている。当社は、GAAPに従って計算された当社の財務実績と対応して見られる非GAAPベースの売上高、売上原価、粗利益、売上総利益、営業利益（損失）、純利益（純損失）および1株当たり利益（損失）という非GAAP財務指標は、投資家にさらなる視点と継続的な業績のより意味のある理解を提供すると考える。さらに、経営幹部は、これらの非GAAP指標を使用して、財務実績をレビューおよび評価し、幹部職員のインセンティブ報酬を決定し、将来の業績を計画および予測する。

▽企業問い合わせ先

Bill Roeschlein

Intermolecular, Inc.

Chief Financial Officer

bill.roeschlein@intermolecular.com

+1 (408) 582-5415

▽投資家問い合わせ先

Matt Glover or NajimMostamand, CFA

Liolios Group, Inc.

IMI@liolios.com

+1 (949) 574-3860

Logo - https://mma.prnewswire.com/media/327096/Intermolecular_Logo.jpg

ソース：Intermolecular, Inc.

Intermolecular Reports First Quarter 2018 Financial Results (Part 1)

PR73449

SAN JOSE, California, May 9, 2018 /PRNewswire=KYODO JBN/ --

-- Company Achieves Third Consecutive Quarter of Positive Adjusted EBITDA

Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials

innovation, today reported results for its first quarter ended March 31, 2018.

Q1 2018 Financial and Operational Highlights

    - Total revenue of $9.7 million, a decrease of 8% over the prior quarter

      and 3% over the same period last year.

    - Program revenues grew 5% sequentially and 36% over the same period last

      year.

    - First quarter adjusted EBITDA of $1.0 million (10% of revenue), compared

      with an adjusted EBITDA loss of $(1.9) million in the same period last

      year.

    - Total cash and investments increased $1.4 million sequentially to $27.2

      million.

    - Secured two new contracts during the quarter.

Management Commentary

"The first quarter of 2018 marked Intermolecular's third consecutive period of

positive adjusted EBITDA, a consistency not seen since 2013," said company

president and CEO, Chris Kramer. "Our improved financial performance is the

result of the actions we have taken over the past year to both increase

customer engagements and reduce our cost structure.  Specifically, on a

year-over-year basis, we increased program services revenue by $2.4 million, or

36% in the quarter, while reducing operating expenses by $4.5 million.  This

combination has more than offset the planned expiration of royalties from

legacy programs and is key for sustainable profitability.  Our engagements with

both existing and new customers continue to expand and we remain confident in

our ability to continue to grow and scale our business profitably."

First Quarter Fiscal 2018 Results

Revenue for the first quarter of 2018 was $9.7 million, down 8% compared to

$10.5 million in the fourth quarter of 2017, and down 3% compared to $9.9

million in the same period a year ago. Program revenues of $9.3 million grew 5%

sequentially and 36% over the same period a year ago.

Net loss for the first quarter of 2018 was $(0.6) million, or $(0.01) per

share, compared to net income of $0.1 million, or $0.00 per share, in the

fourth quarter of 2017, and net loss of $(5.8) million, or $(0.12) per share,

in the same period a year ago.

Non-GAAP net loss for the first quarter of 2018 was $(0.4) million, or $(0.01)

per share, compared to non-GAAP net income of $0.4 million, or $0.01 per share,

in the prior quarter, and non-GAAP net loss of $(5.2) million, or $(0.10) per

share, in the same period a year ago.  

Adjusted EBITDA for the first quarter of 2018 was $1.0 million, compared to

$2.1 million in the prior quarter, and an adjusted EBITDA loss of $(1.9)

million in the same period a year ago.  

Cash and investments were $27.2 million at the end of first quarter of 2018, an

increase of $1.4 million compared to $25.8 million at the end of fourth quarter

of 2017. The company had no debt at quarter end.    

Second Quarter of 2018 Outlook

The following statements are based on Intermolecular's current expectations for

the second quarter ending June 30, 2018. The following statements are

forward-looking, and actual results could differ materially depending on market

conditions and the factors set forth under "Forward-Looking Statements" below.

Intermolecular does not plan to update, nor does it undertake any obligation to

update, this outlook in the future.

    - Revenue is projected to be in the range of $9.8 million to $10.2

      million;

    - Net income is projected to be between a loss of $(0.3) million, or

      $(0.01) per share, and a profit of $0.3 million, or $0.01 per share,

      based on approximately 49.6 million shares expected to be outstanding;

    - Non-GAAP net income, excluding stock-based compensation expense, is

      projected to be between breakeven and $0.6 million, or between $0.00 to

      $0.01 per share based on 49.6 million shares expected to be outstanding;

      and,

    - Adjusted EBITDA is projected to be between $1.2 million and $1.7 million.

Intermolecular reports revenue, cost of revenue, gross margin, operating income

(loss), net income (loss) and earnings (loss) per share in accordance with U.S.

generally accepted accounting principles (GAAP) and additionally on a non-GAAP

basis. A reconciliation of the non-GAAP financial measures with the most

directly comparable GAAP measures, as well as a description of the items

excluded from the non-GAAP measures, is included in the financial statements

portion of this press release. Please refer to "Reconciliation of GAAP to

Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Income/Loss to

Non-GAAP Net Income" below.

Conference Call

Intermolecular will host a conference call and simultaneous audio-only webcast

today (May 8, 2018) at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to

discuss these results. The call will be hosted by Intermolecular President and

CEO Chris Kramer and CFO Bill Roeschlein.

U.S. dial-in number: +1 (877) 251-1860

International dial-in number: +1 (224) 357-2386

Conference ID: 2183689

Please call the conference telephone number five to ten minutes prior to start

time. An operator will register your name and organization. If you have

difficulty connecting with the conference call, please contact Liolios Group at

+1 (949) 574-2386

A live and archived webcast (audio only) of the call will be available on

Intermolecular's website (http://ir.intermolecular.com/ ) for up to 30 days

after the call.

About Intermolecular, Inc.

Intermolecular(R) is the trusted partner for advanced materials innovation.

Advanced materials are at the core of innovation in the 21st century for a wide

range of industries including semiconductors, consumer electronics, automotive

and aerospace. With its substantial materials expertise; accelerated learning

and experimentation platform; and information and analytics infrastructure,

Intermolecular has a ten-year track record helping leading companies accelerate

and de-risk materials innovation. Learn more at www.intermolecular.com.  

"Intermolecular" and the Intermolecular logo are registered trademarks; all

rights reserved.

Forward-Looking Statements

Statements made in this press release and the earnings call referencing the

press release that are not statements of historical fact are forward-looking

statements. Forward-looking statements are subject to the "safe harbor"

provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are commonly identified by words such as "would,"

"may," "expects," "believes," "plans," "intends," "projects" and other terms

with similar meaning. Investors are cautioned that the forward-looking

statements in this document are based on current beliefs, assumptions and

expectations, speak only as of the date of this document and involve risks and

uncertainties that could cause actual results to differ materially from current

expectations. Such statements are subject to certain known and unknown risks

and uncertainties, many of which are difficult to predict and generally beyond

Intermolecular's control, that could cause actual results and other future

events to differ materially from those expressed in, or implied or projected

by, the forward-looking information and statements. Material factors that could

cause actual results to differ materially from current expectations include,

without limitation, the following: our ability to productize our workflows with

existing and future customers; expectations regarding our future revenue, cash

flow and GAAP and non-GAAP net income or loss; financial condition; the ability

of our new business model to generate profits and long-term shareholder

returns; the extent to which technology developed in collaboration with our

customers will continue to remain on the critical path and have significant

value for such customers and us as well as the industry as a whole; and

anticipated growth in our current markets through expansion of existing

customer programs and the entry into other engagements with new customers.

Forward-looking statements are subject to risks and uncertainties that could

cause actual results to differ materially from expectations, including but not

limited to: our ability to execute on our strategy, prove our business model

and remain technologically competitive in rapidly evolving industry conditions;

commercial acceptance of our HPC platform and methodology as effective R&D

tools; our ability to achieve and sustain profitability; the ability of our

customers to achieve their announced product roadmaps in a timely manner; the

extent to which we are able to successfully extend and expand relationships

with existing customers; our ability to manage the growth of our business; the

rapid technology changes and volatility of the customers and industries we

serve; our potential need for future capital to finance our operations; and

other risks described in our most recent annual report on Form 10-K as updated

by our quarterly reports on Form 10-Q and other filings with the Securities and

Exchange Commission available at www.sec.gov, particularly in the sections

titled "Risk Factors." All forward-looking statements are based on management's

current estimates, projections and assumptions, and we assume no obligation to

update them.

Non-GAAP Financial Measures

To supplement the financial data presented on a GAAP basis, we also disclose

certain non-GAAP financial measures, which exclude the effect of stock-based

compensation expense. These non-GAAP financial measures are not prepared in

accordance with GAAP, do not serve as an alternative to GAAP and may be

calculated differently than non-GAAP financial information disclosed by other

companies. These results should only be used to evaluate our results of

operations in conjunction with the corresponding GAAP measures. We believe that

our non-GAAP financial information provides useful information to management

and investors regarding financial and business trends relating to our financial

condition and results of operations because the non-GAAP measures exclude

charges that management considers to be outside of Intermolecular's core

operating results. We believe that the non-GAAP measures of revenue, cost of

net revenue, gross profit, gross margin, operating (loss) income, net (loss)

income, earnings per share and net (loss) income per share, viewed in

combination with our financial results calculated in accordance with GAAP,

provide investors with additional perspective and a more meaningful

understanding of our ongoing operating performance. In addition, management

uses these non-GAAP measures to review and assess financial performance, to

determine executive officer incentive compensation and to plan and forecast

performance in future periods.

Corporate Contact:

Bill Roeschlein

Intermolecular, Inc.

Chief Financial Officer

bill.roeschlein@intermolecular.com

+1 (408) 582-5415

Investor Contact:

Matt Glover or Najim Mostamand, CFA

Liolios Group, Inc.

IMI@liolios.com

+1 (949) 574-3860

Logo - https://mma.prnewswire.com/media/327096/Intermolecular_Logo.jpg

SOURCE: Intermolecular, Inc.